Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus LARGON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus LARGON.
DRIXORAL vs LARGON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Propionazine is a phenothiazine derivative that acts as a central dopamine receptor antagonist, particularly at D2 receptors. It also exhibits antihistaminergic, anticholinergic, and sedative effects by blocking histamine H1 and muscarinic receptors.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
50 mg intramuscularly every 4-6 hours as needed for nausea and vomiting. Maximum: 300 mg/day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life is 20-30 hours in healthy adults, extending up to 40-60 hours in patients with hepatic impairment or elderly.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Primarily renal (approximately 50-80% as unchanged drug and metabolites) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (~10-15%).
Category C
Category C
Antihistamine/Decongestant
Antihistamine